160 related articles for article (PubMed ID: 20591150)
1. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
Ikenberg K; Fritzsche FR; Zuerrer-Haerdi U; Hofmann I; Hermanns T; Seifert H; Müntener M; Provenzano M; Sulser T; Behnke S; Gerhardt J; Mortezavi A; Wild P; Hofstädter F; Burger M; Moch H; Kristiansen G
BMC Cancer; 2010 Jun; 10():341. PubMed ID: 20591150
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; Rübben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
Chromecki TF; Cha EK; Pummer K; Scherr DS; Tewari AK; Sun M; Fajkovic H; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
BJU Int; 2012 Jul; 110(1):63-8. PubMed ID: 22077633
[TBL] [Abstract][Full Text] [Related]
4. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
[TBL] [Abstract][Full Text] [Related]
5. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
7. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas.
Riener MO; Fritzsche FR; Clavien PA; Pestalozzi BC; Probst-Hensch N; Jochum W; Kristiansen G
Hum Pathol; 2009 Oct; 40(10):1377-83. PubMed ID: 19467694
[TBL] [Abstract][Full Text] [Related]
8. IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.
Yan J; Wei Q; Jian W; Qiu B; Wen J; Liu J; Fu B; Zhou X; Zhao T
Lung; 2016 Feb; 194(1):137-46. PubMed ID: 26608347
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater.
Kim HG; Park MS; Sung JY; Kim YW; Kim HS; Na K
Anticancer Res; 2019 Sep; 39(9):4947-4955. PubMed ID: 31519600
[TBL] [Abstract][Full Text] [Related]
10. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.
Hoffmann NE; Sheinin Y; Lohse CM; Parker AS; Leibovich BC; Jiang Z; Kwon ED
Cancer; 2008 Apr; 112(7):1471-9. PubMed ID: 18260086
[TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck.
Clauditz TS; Wang CJ; Gontarewicz A; Blessmann M; Tennstedt P; Borgmann K; Tribius S; Sauter G; Dalchow C; Knecht R; Münscher A; Wilczak W
J Oral Pathol Med; 2013 Feb; 42(2):125-32. PubMed ID: 22643116
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.
Burdelski C; Jakani-Karimi N; Jacobsen F; Möller-Koop C; Minner S; Simon R; Sauter G; Steurer S; Clauditz TS; Wilczak W
Oncol Rep; 2018 Jan; 39(1):3-12. PubMed ID: 29115542
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog signaling protein expression and its association with prognostic parameters in prostate cancer: a retrospective study from the view point of new 2010 anatomic stage/prognostic groups.
Kim TJ; Lee JY; Hwang TK; Kang CS; Choi YJ
J Surg Oncol; 2011 Oct; 104(5):472-9. PubMed ID: 21656527
[TBL] [Abstract][Full Text] [Related]
15. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.
Jeng YM; Chang CC; Hu FC; Chou HY; Kao HL; Wang TH; Hsu HC
Hepatology; 2008 Oct; 48(4):1118-27. PubMed ID: 18802962
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
[TBL] [Abstract][Full Text] [Related]
17. Analysis of IMP3 expression in prostate adenocarcinomas.
Tosun Yildirim H; Sentürk N
Turk Patoloji Derg; 2012; 28(2):128-33. PubMed ID: 22627630
[TBL] [Abstract][Full Text] [Related]
18. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.
Wang L; Li HG; Xia ZS; Lü J; Peng TS
Chin Med J (Engl); 2010 Dec; 123(24):3554-8. PubMed ID: 22166630
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of potential therapeutic targets in prostate cancer.
Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
[TBL] [Abstract][Full Text] [Related]
20. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
